Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.

Author: BorinMarie T, BrooksCarter D, BrussJon B, CassRobert T, HavrillaNancy A, TackKenneth J, YoungDon

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the pharmacokinetics (PK), safety, and tolerability of ACHN-490, an aminoglycoside with activity against multidrug-resistant pathogens, in healthy subjects. The study found that ACHN-490 exhibited linear and dose-proportional PK with no evidence of accumulation over multiple doses. The drug was generally safe and well-tolerated, with no significant nephrotoxicity or ototoxicity observed. The findings support the potential of ACHN-490 as a therapeutic option for multidrug-resistant infections.
Paper Details　
Original Abstract of the Article :
ACHN-490 is an aminoglycoside with activity against multidrug-resistant pathogens, including those resistant to currently used aminoglycosides. Two randomized, double-blind, placebo-controlled clinical studies investigated the pharmacokinetics (PK), safety, and tolerability of ACHN-490 injection in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232771/

データ提供：米国国立医学図書館（NLM）

ACHN-490: A New Oasis in the Desert of Multidrug-Resistant Infections

The fight against [multidrug-resistant pathogens] is a constant battle, as these formidable foes continue to evolve and evade traditional antibiotics. This study investigates the pharmacokinetics and safety of [ACHN-490], a promising new [aminoglycoside] with activity against multidrug-resistant bacteria. Imagine a camel traversing a vast desert, seeking a source of water to quench its thirst and sustain its journey. ACHN-490, in this analogy, represents a new source of hope, potentially offering a lifeline in the fight against multidrug-resistant infections.

ACHN-490: A Promising Weapon in the Arsenal Against Drug-Resistant Infections

The study found that [ACHN-490] exhibited [linear and dose-proportional pharmacokinetics], with a [favorable safety profile]. This suggests that ACHN-490 may be a safe and effective treatment option for infections caused by multidrug-resistant bacteria. The researchers observed [no evidence of nephrotoxicity or ototoxicity] even at the highest dose tested. This is significant, as aminoglycosides are known to have potential side effects on the kidneys and ears. These findings suggest that ACHN-490 may be a valuable addition to the arsenal against drug-resistant infections.

Navigating the Desert of Drug-Resistant Infections: Hope on the Horizon

The study’s findings offer a glimmer of hope in the battle against drug-resistant infections. ACHN-490 represents a promising new agent that could be a valuable weapon in our arsenal against these formidable foes. It is crucial to continue research and development of new antibiotics to combat the ever-evolving challenge of drug resistance. The study’s findings underscore the importance of ongoing innovation in the fight against infectious diseases.

Dr. Camel's Conclusion

This study highlights the promise of ACHN-490 as a new and potentially effective treatment for infections caused by multidrug-resistant bacteria. It provides a beacon of hope in the ongoing battle against drug resistance, reminding us that research and innovation are essential in safeguarding human health.

Date :
  1. Date Completed 2012-03-29
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21911572

DOI: Digital Object Identifier

PMC3232771

Related Literature

Article Analysis
・Effects of plazomicin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.